The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer (NSCLC)?
 
Koichi Ogawa
No Relationships to Disclose
 
Tomoya Kawaguchi
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yasuhiro Koh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Hitachi; Kyowa Hakko Kirin; Novartis; Pfizer; Thermo Fisher Scientific; Tosoh Corporation
Consulting or Advisory Role - Tosoh Corporation
Research Funding - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Novartis; On-chip Biotechnologies; TERUMO; Toppan Printing Co.
 
Shun-Ichi Isa
No Relationships to Disclose
 
Akihito Kubo
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Novartis; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
 
Masahiko Ando
Consulting or Advisory Role - Asahi Kasei
Research Funding - Kyowa Hakko Kirin (Inst)
 
Hideo Saka
Honoraria - Amco; AstraZeneca; Becton Dickinson; Boehringer Ingelheim; Boston Scientific; Chugai Pharma; Kyorin; Kyowahakko Kirin; Lilly; MSD K.K; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Harada (Inst); Lilly (Inst); MSD K.K (Inst); Olympus (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Parexel (Inst)
 
Naoki Yoshimoto
No Relationships to Disclose
 
Akihide Matsumura
No Relationships to Disclose
 
Hiroyasu Kaneda
No Relationships to Disclose
 
Akihiro Tamiya
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kissei Pharmaceutical; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yoshihiko Taniguchi
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; MSD; Mundipharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kenji Sawa
No Relationships to Disclose
 
Yoshiya Matsumoto
No Relationships to Disclose
 
Motohiro Izumi
No Relationships to Disclose